Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209116 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12466620 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL799468 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL301501 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4203114 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12646402 | 0.94 | FFAR1 (0.73) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1550383 | 0.90 | FFAR1 (1.00) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21845792 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL799523 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16232159 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9790195-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | FFAR1 2319/4885ALDH1A1 253/4885CYP1A2 820/4885 |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | FFAR1 4334/4885ALDH1A1 734/4885CYP1A2 3176/4885 |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | FFAR1 4403/4885ALDH1A1 969/4885CYP1A2 3261/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | FFAR1 4334/4885ALDH1A1 734/4885CYP1A2 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.